The same PCR products obtained previously for the Sanger sequencing of the NS3/4 A, NS5A and NS5B regions were analyzed using a next generation sequencing (NGS) approach. Samples from 15 DAA failing patients as well as 15 untreated patients with at least 10000 HCV copies/ml were analyzed by NGS.
HCV amplicons (20 µL) were purified using 36 µL Agencourt AMPure XP beads (Beckman Coulter Inc). Amplicon concentrations were determined with the Invitrogen™ Quant-iT™ PicoGreen® dsDNA Assay (Invitrogen, Inc.). Purified amplicons were diluted to 5.0 ng/µl and 2 µL were processed using the Illumina Nextera XT DNA Library Preparation Kit (Illumina Inc.) and uniquely indexed using the Illumina Nextera XT Index Kit (96 Index). All amplified Nextera-PCR products were purified using Agencourt AMPure XP beads (Beckman Coulter Inc.). All recovered DNA was pooled in equal volumes at a normalized concentration (1.43 ng/µl, the lowest concentration recovered). The DNA concentration of the pool was determined using the Invitrogen™ Quant-iT™ PicoGreen® dsDNA Assay (Invitrogen,Inc.). Library quality was determined using a Bioanalyzer 2100 (Agilent Technologies) and was sequenced on a MiSeq deep sequencing platform (Illumina, San Diego, CA) using a the 500-cycle MiSeq reagent kit v2.Fastq files were generated using the onboard MiSeq Reporter.
+ Open protocol